ArticleJAAD case reports2025

Use of dupilumab to manage a grade 3 cutaneous adverse effect from enfortumab vedotin/pembrolizumab treatment in a patient with metastatic urothelial carcinoma.

Maura C Gillis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.